NASDAQ:CLLSCellectis Stock Price, Forecast & News

Cellectis' stock was trading at $11.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLLS shares have increased by 50.7% and is now trading at $17.22.
View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cellectis.

Cellectis is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Cellectis.

Cellectis SA (NASDAQ:CLLS) released its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported $0.47 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.59) by $1.06. The biotechnology company earned $51.91 million during the quarter, compared to analysts' expectations of $21.07 million. Cellectis had a negative return on equity of 18.00% and a negative net margin of 89.50%.
View Cellectis' earnings history.

7 Wall Street analysts have issued 1-year target prices for Cellectis' stock. Their forecasts range from $11.00 to $73.00. On average, they expect Cellectis' share price to reach $32.17 in the next year. This suggests a possible upside of 86.8% from the stock's current price.
View analysts' price targets for Cellectis.

News articles about CLLS stock have trended neutral on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cellectis earned a news impact score of 0.2 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
View the latest news about Cellectis.

Cellectis saw a increase in short interest in January. As of January 31st, there was short interest totaling 261,800 shares, an increase of 15.4% from the January 15th total of 226,800 shares. Based on an average daily trading volume, of 130,300 shares, the days-to-cover ratio is currently 2.0 days. Currently, 0.6% of the company's shares are short sold.
View Cellectis' Short Interest.

Some companies that are related to Cellectis include Twist Bioscience (TWST), Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Legend Biotech (PCVX), Mesoblast (MESO), Sangamo Therapeutics (SGMO), BAVARIAN NORDIC/S (BVNRY), Revolution Medicines (RVMD), Coherus Biosciences (CHRS), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Vaxart (VXRT), Cortexyme (CRTX) and Regenxbio (RGNX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Calyxt (CLXT), NVIDIA (NVDA), Gilead Sciences (GILD), Editas Medicine (EDIT), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), Micron Technology (MU), Sarepta Therapeutics (SRPT) and Intellia Therapeutics (NTLA).

(CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Cellectis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (1.73%), New York State Common Retirement Fund (0.25%), Vident Investment Advisory LLC (0.20%), Vident Investment Advisory LLC (0.20%), Envestnet Asset Management Inc. (0.16%) and Eqis Capital Management Inc. (0.10%).

CLLS stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., UBS Group AG, Vident Investment Advisory LLC, Vident Investment Advisory LLC, Trexquant Investment LP, and Eqis Capital Management Inc..

CLLS stock was bought by a variety of institutional investors in the last quarter, including RMB Capital Management LLC, Exchange Traded Concepts LLC, Princeton Capital Management LLC, Mitsubishi UFJ Kokusai Asset Management Co. Ltd., New York State Common Retirement Fund, and Envestnet Asset Management Inc..

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLLS stock can currently be purchased for approximately $17.22.

Cellectis has a market capitalization of $731.26 million and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Cellectis employs 161 workers across the globe.

The official website for Cellectis is www.cellectis.com.

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]